Evidence map›Paper›PMID 26581035›Full record

ArticlePLoS biology2015

Quantifying the Determinants of Evolutionary Dynamics Leading to Drug Resistance.

Guillaume Chevereau, Marta Dravecká, Tugce Batur, Aysegul Guvenek, Dilay Hazal Ayhan, Erdal Toprak, Tobias Bollenbach

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 130 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Guillaume ChevereauIST Austria, Am Campus 1, Klosterneuburg, Austria.
Marta DraveckáIST Austria, Am Campus 1, Klosterneuburg, Austria.
Tugce BaturFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Aysegul GuvenekFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Dilay Hazal AyhanFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Erdal ToprakFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Tobias BollenbachIST Austria, Am Campus 1, Klosterneuburg, Austria.
Sabancı Üniversitesi · TRInstitute of Science and Technology Austria · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug resistant pathogens is a serious public health problem. It is a long-standing goal to predict rates of resistance evolution and design optimal treatment strategies accordingly. To this end, it is crucial to reveal the underlying causes of drug-specific differences in the evolutionary dynamics leading to resistance. However, it remains largely unknown why the rates of resistance evolution via spontaneous mutations and the diversity of mutational paths vary substantially between drugs. Here we comprehensively quantify the distribution of fitness effects (DFE) of mutations, a key determinant of evolutionary dynamics, in the presence of eight antibiotics representing the main modes of action. Using precise high-throughput fitness measurements for genome-wide Escherichia coli gene deletion strains, we find that the width of the DFE varies dramatically between antibiotics and, contrary to conventional wisdom, for some drugs the DFE width is lower than in the absence of stress. We show that this previously underappreciated divergence in DFE width among antibiotics is largely caused by their distinct drug-specific dose-response characteristics. Unlike the DFE, the magnitude of the changes in tolerated drug concentration resulting from genome-wide mutations is similar for most drugs but exceptionally small for the antibiotic nitrofurantoin, i.e., mutations generally have considerably smaller resistance effects for nitrofurantoin than for other drugs. A population genetics model predicts that resistance evolution for drugs with this property is severely limited and confined to reproducible mutational paths. We tested this prediction in laboratory evolution experiments using the "morbidostat", a device for evolving bacteria in well-controlled drug environments. Nitrofurantoin resistance indeed evolved extremely slowly via reproducible mutations-an almost paradoxical behavior since this drug causes DNA damage and increases the mutation rate. Overall, we identified novel quantitative characteristics of the evolutionary landscape that provide the conceptual foundation for predicting the dynamics of drug resistance evolution.

Indexed as

Drug Resistance, BacterialEvolution, MolecularModels, GeneticAlgorithmsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli K12Escherichia coli ProteinsGene DeletionGenetic FitnessMicrobial Sensitivity TestsMutagensMutationMutation RateNitrofurantoinAnti-Bacterial AgentsEscherichia coli ProteinsMutagensNitrofurantoin

Identifiers

PMID26581035
PMCPMC4651364
OpenAlexW2176937892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.